- Acadia Pharmaceuticals Implies Sanuwave Could Triple On New Study Design
- Recognizing Leadership In Biotech: A Critical Facet Of The Diligence Process
- Looking Beyond The JPM Global Healthcare Conference: More Biotech Than Meets The Eye
- Canadian Biotech Isn't Dead; Following The Money To Undervalued Equities
- Prolor Biotech To Benefit From 'Bio-Better' Drug As Novo Nordisk Pulls Out
Nouvelle Asset Management
Nouvelle Asset Management
Stop FollowingNouvelle Asset Management
ABOUT
With a focus on out-of-favor equities in the volatile high-technology, biotechnology, and natural resources sectors, we invest in companies with hidden deep value. The fund is led by a veteran researcher, whose core competency is in unraveling murky stories and strategically sifting through fundamentals.
With our experience, we hope to help readers discover alpha in areas most investors are not - or refuse to be - looking.
With our experience, we hope to help readers discover alpha in areas most investors are not - or refuse to be - looking.
SNAPSHOT
- Description: Mutual fund manager.
- Interests: Commodities, Stocks - long, Stocks - short
COMPANY
Currently, there is no company profile for Nouvelle Asset Management.
BLOG
Currently, there are no blog details for Nouvelle Asset Management.
Book
Currently, there are no book details for Nouvelle Asset Management.
Latest comments on Nouvelle Asset's Articles
- Jack Wildcat on Acadia Pharmaceuticals Implies Sanuwave Could T...
- D. Mero on Acadia Pharmaceuticals Implies Sanuwave Could T...
- Brian Marckx on Acadia Pharmaceuticals Implies Sanuwave Could T...
- PICOLOMINI on Acadia Pharmaceuticals Implies Sanuwave Could T...
- atrickpay on Recognizing Leadership In Biotech: A Critical F...
LATEST ARTICLES & INSTAPOSTS
more ยป
